The purpose of this study is to evaluate the clinical outcomes of transcatheter aortic valve Replacement (TAVR) in the Asian Pacific population
Study Type
OBSERVATIONAL
Enrollment
2,000
Queen Elizabeth Hospital
Hong Kong, China
Nanjing 1st Hospital
Nanjing, China
Shonan Kamakura General Hospital
Kamakura, Japan
Institut Jantung Negara
Kuala Lumpur, Malaysia
Death from any cause
Time frame: 1 month
Death from any cause
Time frame: 6 months
Death from any cause
Time frame: 1 year
Death from any cause
Time frame: 2 years
Death from any cause
Time frame: 3 years
Death from any cause
Time frame: 4 years
Death from any cause
Time frame: 5 years
Death from cardiac cause
Time frame: 1 month
Death from cardiac cause
Time frame: 6 months
Death from cardiac cause
Time frame: 1 year
Death from cardiac cause
Time frame: 2 years
Death from cardiac cause
Time frame: 3 years
Death from cardiac cause
Time frame: 4 years
Death from cardiac cause
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
St. Luke's Medical Center
Bonifacio, Philippines
National Heart Centre of Singapore
Singapore, Singapore
National University Heart Centre
Singapore, Singapore
Asan Medical Center
Seoul, South Korea
National Taiwan University
Taipei, Taiwan
King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Time frame: 5 years
Stroke
Time frame: 1 month
Stroke
Time frame: 6 months
Stroke
Time frame: 1 year
Stroke
Time frame: 2 years
Stroke
Time frame: 3 years
Stroke
Time frame: 4 years
Stroke
Time frame: 5 years
Myocardial infarction
Time frame: 1 month
Myocardial infarction
Time frame: 6 months
Myocardial infarction
Time frame: 1 year
Myocardial infarction
Time frame: 2 years
Myocardial infarction
Time frame: 3 years
Myocardial infarction
Time frame: 4 years
Myocardial infarction
Time frame: 5 years
Repeat hospitalization
Time frame: 1 month
Repeat hospitalization
Time frame: 6 months
Repeat hospitalization
Time frame: 1 year
Repeat hospitalization
Time frame: 2 years
Repeat hospitalization
Time frame: 3 years
Repeat hospitalization
Time frame: 4 years
Repeat hospitalization
Time frame: 5 years
Acute kidney injury
Time frame: 1 month
Acute kidney injury
Time frame: 6 months
Acute kidney injury
Time frame: 1 year
Acute kidney injury
Time frame: 2 years
Acute kidney injury
Time frame: 3 years
Acute kidney injury
Time frame: 4 years
Acute kidney injury
Time frame: 5 years
Vascular complication
Time frame: 1 month
Vascular complication
Time frame: 6 months
Vascular complication
Time frame: 1 year
Vascular complication
Time frame: 2 years
Vascular complication
Time frame: 3 years
Vascular complication
Time frame: 4 years
Vascular complication
Time frame: 5 years
Bleeding events
Time frame: 1 month
Bleeding events
Time frame: 6 months
Bleeding events
Time frame: 1 year
Bleeding events
Time frame: 2 years
Bleeding events
Time frame: 3 years
Bleeding events
Time frame: 4 years
Bleeding events
Time frame: 5 years
Device success
Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \< 3 m/s, and no moderate or severe paravalvular regurgitation)
Time frame: 1 month
Device success
Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \< 3 m/s, and no moderate or severe paravalvular regurgitation)
Time frame: 6 months
Device success
Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \< 3 m/s, and no moderate or severe paravalvular regurgitation)
Time frame: 1 year
Device success
Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \< 3 m/s, and no moderate or severe paravalvular regurgitation)
Time frame: 2 years
Device success
Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \< 3 m/s, and no moderate or severe paravalvular regurgitation)
Time frame: 3 years
Device success
Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \< 3 m/s, and no moderate or severe paravalvular regurgitation)
Time frame: 4 years
Device success
Absence of procedural mortality and correct positioning of a single prosthetic valve into the proper anatomical location with intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient \<20 mmHg or peak velocity \< 3 m/s, and no moderate or severe paravalvular regurgitation)
Time frame: 5 years